메뉴 건너뛰기




Volumn 29, Issue 5, 2001, Pages 1086-1087

Therapy of pulmonary hypertension: Targeting pathogenic mechanisms with selective treatment delivery

Author keywords

Pulmonary hypertension; Therapy

Indexed keywords

PROSTACYCLIN DERIVATIVE; PROSTANOID; SILDENAFIL;

EID: 0035025405     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200105000-00047     Document Type: Editorial
Times cited : (5)

References (14)
  • 3
    • 0029055964 scopus 로고
    • Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension
    • (1995) N Engl J Med , vol.333 , pp. 214-221
    • Giaid, A.1    Saleh, D.2
  • 5
    • 0033817459 scopus 로고    scopus 로고
    • Heterozygous germline mutations in BMPR2, encoding a TGF beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium
    • (2000) Nat Genet , vol.26 , pp. 81-84
    • Lane, K.B.1    Machado, R.D.2    Pauciulo, M.W.3
  • 8
    • 0342871960 scopus 로고    scopus 로고
    • Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension
    • (1997) Circulation , vol.96 , pp. 2782-2784
    • Friedman, R.1    Mears, J.G.2    Barst, R.J.3
  • 9
    • 0031869664 scopus 로고    scopus 로고
    • Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension
    • (1998) Eur Resp J , vol.12 , pp. 265-270
    • Sitbon, O.1    Humbert, M.2    Jagot, J.L.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.